355 related articles for article (PubMed ID: 26207349)
1. Long-term sustained disease control in patients with mantle cell lymphoma with or without active disease after treatment with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.
Vaughn JE; Sorror ML; Storer BE; Chauncey TR; Pulsipher MA; Maziarz RT; Maris MB; Hari P; Laport GG; Franke GN; Agura ED; Langston AA; Rezvani AR; Storb R; Sandmaier BM; Maloney DG
Cancer; 2015 Oct; 121(20):3709-16. PubMed ID: 26207349
[TBL] [Abstract][Full Text] [Related]
2. Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation.
Baron F; Storb R; Storer BE; Maris MB; Niederwieser D; Shizuru JA; Chauncey TR; Bruno B; Forman SJ; McSweeney PA; Maziarz RT; Pulsipher MA; Agura ED; Wade J; Sorror M; Maloney DG; Sandmaier BM
J Clin Oncol; 2006 Sep; 24(25):4150-7. PubMed ID: 16896000
[TBL] [Abstract][Full Text] [Related]
3. Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma.
Maris MB; Sandmaier BM; Storer BE; Chauncey T; Stuart MJ; Maziarz RT; Agura E; Langston AA; Pulsipher M; Storb R; Maloney DG
Blood; 2004 Dec; 104(12):3535-42. PubMed ID: 15304387
[TBL] [Abstract][Full Text] [Related]
4. Impact of hematopoietic stem cell transplantation in patients with relapsed or refractory mantle cell lymphoma.
Yamasaki S; Chihara D; Kim SW; Izutsu K; Iwato K; Fukuda T; Uchida N; Amano I; Nakazawa H; Kuroda J; Hashimoto H; Ichinohe T; Kanda Y; Atsuta Y; Suzumiya J; Suzuki R
Ann Hematol; 2018 Aug; 97(8):1445-1452. PubMed ID: 29610968
[TBL] [Abstract][Full Text] [Related]
5. Comparison of 2 Carmustine-Containing Regimens in the Rituximab Era: Excellent Outcomes Even in Poor-Risk Patients.
Caimi PF; William BM; Silva Rondon CH; Fu P; Cooper BW; Campagnaro EL; Gerson SL; Reese-Koc J; Fox R; Creger RJ; de Lima M; Lazarus HM
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1926-31. PubMed ID: 26087475
[TBL] [Abstract][Full Text] [Related]
6. Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for Blood and Marrow Transplantation.
Cook G; Smith GM; Kirkland K; Lee J; Pearce R; Thomson K; Morris E; Orchard K; Rule S; Russell N; Craddock C; Marks DI;
Biol Blood Marrow Transplant; 2010 Oct; 16(10):1419-27. PubMed ID: 20399879
[TBL] [Abstract][Full Text] [Related]
7. Nonmyeloablative unrelated donor hematopoietic cell transplantation to treat patients with poor-risk, relapsed, or refractory multiple myeloma.
Georges GE; Maris MB; Maloney DG; Sandmaier BM; Sorror ML; Shizuru JA; Lange T; Agura ED; Bruno B; McSweeney PA; Pulsipher MA; Chauncey TR; Mielcarek M; Storer BE; Storb R
Biol Blood Marrow Transplant; 2007 Apr; 13(4):423-32. PubMed ID: 17287157
[TBL] [Abstract][Full Text] [Related]
8. Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma.
Burroughs LM; O'Donnell PV; Sandmaier BM; Storer BE; Luznik L; Symons HJ; Jones RJ; Ambinder RF; Maris MB; Blume KG; Niederwieser DW; Bruno B; Maziarz RT; Pulsipher MA; Petersen FB; Storb R; Fuchs EJ; Maloney DG
Biol Blood Marrow Transplant; 2008 Nov; 14(11):1279-87. PubMed ID: 18940683
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the center for international blood and marrow transplant research.
Hamadani M; Saber W; Ahn KW; Carreras J; Cairo MS; Fenske TS; Gale RP; Gibson J; Hale GA; Hari PN; Hsu JW; Inwards DJ; Kamble RT; Klein A; Maharaj D; Marks DI; Rizzieri DA; Savani BN; Schouten HC; Waller EK; Wirk B; Lazarus HM
Biol Blood Marrow Transplant; 2013 Apr; 19(4):625-31. PubMed ID: 23333532
[TBL] [Abstract][Full Text] [Related]
10. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.
Koh LP; Chen CS; Tai BC; Hwang WY; Tan LK; Ng HY; Linn YC; Koh MB; Goh YT; Tan B; Lim S; Lee YM; Tan KW; Liu TC; Ng HJ; Loh YS; Mow BM; Tan DC; Tan PH
Biol Blood Marrow Transplant; 2007 Jul; 13(7):790-805. PubMed ID: 17580257
[TBL] [Abstract][Full Text] [Related]
11. Total Body Irradiation Is Safe and Similarly Effective as Chemotherapy-Only Conditioning in Autologous Stem Cell Transplantation for Mantle Cell Lymphoma.
Tseng YD; Stevenson PA; Cassaday RD; Cowan A; Till BG; Shadman M; Graf SA; Ermoian R; Smith SD; Holmberg LA; Press OW; Gopal AK
Biol Blood Marrow Transplant; 2018 Feb; 24(2):282-287. PubMed ID: 29061536
[TBL] [Abstract][Full Text] [Related]
12. Non-myeloablative allogeneic hematopoietic stem cell transplantation for adults with relapsed and refractory mantle cell lymphoma: a single-center analysis in the rituximab era.
Mussetti A; Devlin SM; Castro-Malaspina HR; Barker JN; Giralt SA; Zelenetz AD; Sauter CS; Perales MA
Bone Marrow Transplant; 2015 Oct; 50(10):1293-1298. PubMed ID: 26146802
[TBL] [Abstract][Full Text] [Related]
13. Nonmyeloablative allogeneic hematopoietic stem cell transplant for the treatment of patients with hematologic malignancies using busulfan, fludarabine, and total body irradiation conditioning is effective in an elderly and infirm population.
Brammer JE; Stentz A; Gajewski J; Curtin P; Hayes-Lattin B; Kovacsovics T; Leis JF; Meyers G; Nemecek E; Subbiah N; Frires R; Palmbach G; Avraham GP; Slater S; Maziarz RT
Biol Blood Marrow Transplant; 2015 Jan; 21(1):89-96. PubMed ID: 25445641
[TBL] [Abstract][Full Text] [Related]
14. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
15. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning.
Baron F; Lechanteur C; Willems E; Bruck F; Baudoux E; Seidel L; Vanbellinghen JF; Hafraoui K; Lejeune M; Gothot A; Fillet G; Beguin Y
Biol Blood Marrow Transplant; 2010 Jun; 16(6):838-47. PubMed ID: 20109568
[TBL] [Abstract][Full Text] [Related]
16. Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte antigen mismatch.
Slack JL; Dueck AC; Fauble VD; Sproat LO; Reeder CB; Noel P; Khera N; Betcher JA; Klein JL; Leis JF; Adams RH
Biol Blood Marrow Transplant; 2013 Aug; 19(8):1167-74. PubMed ID: 23664940
[TBL] [Abstract][Full Text] [Related]
17. Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma.
Rezvani AR; Storer B; Maris M; Sorror ML; Agura E; Maziarz RT; Wade JC; Chauncey T; Forman SJ; Lange T; Shizuru J; Langston A; Pulsipher MA; Sandmaier BM; Storb R; Maloney DG
J Clin Oncol; 2008 Jan; 26(2):211-7. PubMed ID: 18056679
[TBL] [Abstract][Full Text] [Related]
18. Low nonrelapse mortality and prolonged long-term survival after reduced-intensity allogeneic stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma: report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
Sirvent A; Dhedin N; Michallet M; Mounier N; Faucher C; Yakoub-Agha I; Mohty M; Robin M; Tabrizi R; Clement L; Bilger K; Larosa F; Contentin N; Huyn A; François S; Bulabois CE; Ceballos P; Bourrhis JH; Buzyn A; Cornillon J; Guillerm G; de Revel T; Bay JO; Guilhot F; Milpied N
Biol Blood Marrow Transplant; 2010 Jan; 16(1):78-85. PubMed ID: 19744569
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic hematopoietic transplantation for mantle-cell lymphoma: molecular remissions and evidence of graft-versus-malignancy.
Khouri IF; Lee MS; Romaguera J; Mirza N; Kantarjian H; Korbling M; Albitar M; Giralt S; Samuels B; Anderlini P; Rodriguez J; von Wolff B; Gajewski J; Cabanillas F; Champlin R
Ann Oncol; 1999 Nov; 10(11):1293-9. PubMed ID: 10631455
[TBL] [Abstract][Full Text] [Related]
20. Allografting after nonmyeloablative conditioning as a treatment after a failed conventional hematopoietic cell transplant.
Feinstein LC; Sandmaier BM; Maloney DG; Maris MB; Gooley TA; Chauncey TR; Hegenbart U; McSweeney PA; Stuart MJ; Forman SJ; Agura EA; Pulsipher MA; Blume KG; Niederwieser DW; Storb RF
Biol Blood Marrow Transplant; 2003 Apr; 9(4):266-72. PubMed ID: 12720219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
